CytoSorbents Reports Outcomes From A Randomized Controlled Trial Using CytoSorb Blood Purification During Heart Transplant, Recently Published In The European Society Of Cardiology Journal, ESC Heart Failure

Author: Benzinga Newsdesk | January 17, 2024 08:18am

1. Better hemodynamic stability and lower rates of post-operative shock
   • Patients in the CytoSorb group had lower median Vasoactive-Inotropic Scores (27.2 [14.6–47.7] vs. 41.9 [22.4–63.2], p=0.046) and Vasoplegic Syndrome rates (20.0% vs 48.0% control, p=0.028)
   • The odds of early Vasoplegic Syndrome were 6.4 times lower in the CytoSorb group (p=0.029).
2. Shorter median time on mechanical ventilation
   • 25 [19–68.8] hours vs. 65 [23–287] hours in control, p=0.025
3. Lower rates of acute kidney injury (AKI) and need for renal replacement therapy (RRT)
   • AKI: 36.7% vs. 76.0% control, p=0.004
   • Renal replacement therapy: 0% vs. 16.0% control, p=0.037
4. Shorter median time in the ICU
   • 8.5 [8.0–10.3] days vs. 12 [8.5–18.0] days in control, p=0.022
5. No relevant removal of the anti-rejection drug mycophenolic acid (MPA)
6. Similar rates of cardiac allograft rejection, 30-day mortality, and 1-year survival between groups
7. There were no reported device-related adverse events during the study period

Posted In: CTSO